Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 4 the annual report of 2021 will be released on the evening of April 29. During the reporting period, the company achieved an operating revenue of 4.127 billion yuan and a net profit attributable to shareholders of listed companies of 332 million yuan. The company plans to pay a cash dividend of 1.06 yuan (including tax) for every 10 shares.
In 2021, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) further strengthen scientific and technological research and development. The company’s “one center, four institutes” science and technology R & D system has been fully completed, and new achievements have been made in industrial structure adjustment and product pipeline optimization driven by scientific and technological innovation. The company has made new breakthroughs in generic drug R & D, innovative drug R & D, in-hospital preparation development, pharmaceutical variety M & A and joint development, upgrading and development of existing varieties and other important fields. In terms of product M & A, we have completed the M & A of several traditional Chinese medicine varieties. The research projects of chemical medicine innovative drugs, traditional Chinese medicine innovative drugs and chemical medicine generic drugs are promoted together to form a product pipeline of echelon supplement.
The company accelerated the optimization and adjustment of production capacity structure and variety structure of each production base to realize regional resource integration, complementary advantages and cost control; Actively adapt to the new situation of centralized drug purchase, formulate the market development strategy of “self support + all channels + all terminals”, and comprehensively build an independent and controllable marketing network covering the whole country; Continue to optimize the product structure, while maintaining the stock of the main market channels, actively promote the in-hospital preparations and traditional Chinese medicine decoction pieces projects, implement the medical insurance reimbursement and adjustment policies, and cultivate and form new benefit growth points.
The company continues to optimize the industrial positioning, profit model and market value of Anhui Bozhou trading center and Heilongjiang Harbin traditional Chinese medicine commodity trading center. Two large and medium-sized pharmaceutical industry platforms, one south and one north, will spare no effort to build a new platform for the development of China’s traditional Chinese medicine industry.
According to the strategic development layout of “combination of industry and finance”, the company’s fixed increase and raise investment projects driven by scientific and technological innovation were successfully completed, raising a total of 1.238 billion yuan. At the same time, an investment cooperation agreement was signed with Zhejiang teres pharmaceutical industry, and the project of Hangzhou biological drug R & D base was successfully implemented, marking the new track of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) formal layout of biological drug industry.
In order to do a good job in the key work of 2022, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) n n n said that the company will combine high-quality R & D resources at home and abroad, take the development of products with accurate curative effect and leading technology as the orientation, focus on the fields of cardiovascular, cerebrovascular, respiratory, orthopaedics, tumor, digestive system, diabetes and psychoneurosis, comprehensively upgrade the product structure and product pipeline, and form a variety echelon.
Among them, in terms of traditional Chinese medicine, the secondary development of traditional Chinese medicine varieties is carried out around the existing large varieties and potential varieties to promote the filing and registration of hospital preparation products; We will continue to promote the development of innovative traditional Chinese medicine projects such as qingjianghewei formula. In terms of chemical medicine, establish a special preparation research and development platform through introduction and technical cooperation, and carry out the research and development of high-end oral solid preparations, special preparations and products with their own intellectual property rights; Re demonstrate the existing generic drugs and API products based on the cost core point, and carry out the development of high value-added, high technical barriers and characteristic API, so as to effectively reduce the production cost. In terms of product introduction, we will look for M & A opportunities around the company’s development strategy, accelerate the introduction of overseas varieties and the M & A of Chinese high-quality targets, and further enrich the product pipeline.
The company will continue to promote the upgrading of intelligent manufacturing industry, optimize production and manufacturing processes, improve production processes, increase electronic procurement, reduce production and procurement costs and build product cost advantages while ensuring and continuously improving product quality.
The company will take the marketing mode of “fine investment management + independent marketing” and professional chemical marketing as the traction to widely cover medical institutions and retail terminals across the country; Carry out the marketing strategy of fighting in different lines and advancing in both depth and breadth, carry out professional chemical marketing around grade hospitals, and deeply layout grade medical institutions; Go deep into the primary medical market and speed up the expansion of medical terminals and the sinking of channels; Retail channel takes chain drugstores as the key customer target and develops out of hospital sales channels.
In addition, relying on the whole industrial chain layout of “n + 50” traditional Chinese medicine, focusing on northern medicine, Anhui medicine and Longyao, accelerate the cooperation and processing layout of producing areas, integrate national genuine medicinal materials resources, and create the advantages of upstream supply chain of traditional Chinese medicine; Relying on the shennongcang entity of Bozhou traditional Chinese medicine trading center, the Internet platform for bulk trading of traditional Chinese medicine and the B2B traditional Chinese medicine trading platform of Shennonggu, accelerate the construction of an “entity + Internet” Internet platform for the traditional Chinese medicine industry.
That night, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) also disclosed the first quarterly report of 2022. During the reporting period, the company achieved an operating revenue of 1.004 billion yuan, a year-on-year increase of 38.07%; The net profit attributable to the shareholders of the listed company was 158 million yuan, an increase of 1.72% over the same period last year.
